Weeks 1-4: minimal weight loss (2-4 pounds), mild appetite changes
(We know this question may sound grammatically wrong, but we just had to stick to the exact framing of how people are asking questions on the internet.) Moving from 2.4mg Wegovy, the peak dose available (until Jan 2026), to Mounjaro, tells your prescriber a lot about where you are in your treatment journey
Cardio and protein matter, but if we had to prioritize, lifting weights changes physiology in ways that resistance training uniquely supports especially when someone is using appetite-suppressing medications or is at risk for sarcopenia
By understanding both your genetic predispositions and your current inflammatory status, you and your provider can have a more informed discussion about whether compounded GLP-1 options from licensed 503A pharmacies might fit into a carefully monitored treatment plan
The official advice from the MHRA is clear: GLP-1 medicines should not be taken by people who are breastfeeding
Coverage for weight loss indications remains limited across most major plans